10x Genomics, Inc. IPO

10x Genomics is a biotechnology company offering a range of products including software and hardware all aimed at better understanding biological systems.

Register for Details

For more details on financing and valuation of private companies similar to 10x Genomics, Inc. before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About 10x Genomics, Inc.

To invest in 10x Genomics, Inc. pre-IPO

Can you invest in 10x Genomics, Inc. pre-IPO?

You may invest in 10x Genomics, Inc. as it is a public company listed on the NASDAQ with ticker TXG. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of 10x Genomics, Inc. before it goes public?

You can no longer sell shares of 10x Genomics, Inc. on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my 10x Genomics, Inc. shares?

Forge can no longer determine the value of 10x Genomics, Inc. shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is 10x Genomics, Inc. a publicly traded company?

10x Genomics, Inc. became a public company following its IPO on 09/12/2019 and is now traded on the NASDAQ under the ticker TXG.

To learn more about 10x Genomics, Inc. potential IPO

Will 10x Genomics, Inc. go IPO?

10x Genomics, Inc. became a public company following its IPO on 09/12/2019 and is now traded on the NASDAQ under the ticker TXG.

What is 10x Genomics, Inc.’s IPO price?

The IPO price of 10x Genomics, Inc. is not currently available.

When was 10x Genomics, Inc. founded?

10x Genomics, Inc. was founded in 2012.

What is 10x Genomics, Inc. funding to date?

10x Genomics, Inc. has raised $222.59MM to date.

10x Genomics, Inc. Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
01/07/2019 Series D-1 $35MM $xx.xx $1.34B Fidelity, Meritech Capital, Wells Fargo
Price per Share
$xx.xx
Shares Outstanding
2,749,411
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity, Meritech Capital, Wells Fargo
04/26/2018 Series D $50MM $xx.xx $1.31B Fidelity International, Meritech Capital Partners, Paladin Capital Group, Phoenix International Investments, Softbank Capital, Wells Fargo
Price per Share
$xx.xx
Shares Outstanding
5,224,660
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity International, Meritech Capital Partners, Paladin Capital Group, Phoenix International Investments, Softbank Capital, Wells Fargo
03/17/2016 Series C $55MM $xx.xx $400.05MM Fidelity Management & Research Company, Foresite Capital Management, Js Capital Management, Paladin Capital Group, Softbank Capital, Venrock
Price per Share
$xx.xx
Shares Outstanding
12,281,720
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity Management & Research Company, Foresite Capital Management, Js Capital Management, Paladin Capital Group, Softbank Capital, Venrock
01/12/2015 Series B $55.5MM $xx.xx $222MM Foresite Capital Management, Morgan Stanley Alternative Investment Partners, Paladin Capital Group, Venrock, Vital Venture Capital
Price per Share
$xx.xx
Shares Outstanding
16,972,477
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital Management, Morgan Stanley Alternative Investment Partners, Paladin Capital Group, Venrock, Vital Venture Capital
10/30/2013 Series A-2 $22.4MM $xx.xx $56.05MM Foresite Capital Management, Paladin Capital Group
Price per Share
$xx.xx
Shares Outstanding
20,486,543
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital Management, Paladin Capital Group
10/17/2012 Series A-1 $4.69MM $xx.xx $2.78MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
5,523,394
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Dec 30, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.